GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2011

AstraZeneca Turns to Kinaxo to Study PTMs Related to an Oncology Program

  • AstraZeneca and Kinaxo have entered into an agreement in which Kinaxo will employ its high-end mass spectrometry-based technologies to quantitatively analyze post-translational modifications (PTMs) in proteins on a proteome-wide scale in support of one of AstraZeneca’s oncology programs.

    Kinaxo’s Cellular Target Profiling technology employs a combination of quantitative mass spectrometry and software applications to analyze proteome-wide PTM patterns in vivo. The platform provides insights into small molecule target interactions and binding affinities across the proteome of any given cell line or tissue sample, according to the firm. In addition, the compound’s protein targets are determined in a physiological context.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »